Integrating Pharmacogenomic Insights in GLP‐1 Receptor Agonist Therapy: Direct GLP1R and ARRB1 Variants and Indirect CYP2D6 Influences in Personalized Obesity Management

Documenti analoghi

• The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
  di: Nila Ganamurali, et al.
  Pubblicazione: (2026)
• Real‐World Cardiovascular Outcomes of GLP ‐1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer
  di: Cyrille K. Cornelio, et al.
  Pubblicazione: (2026)
• SGLT2 Inhibitors and GLP‐1 Receptor Agonists After Acute Kidney Injury: A Systematic Review With Meta‐Analysis
  di: Erin F. Barreto, et al.
  Pubblicazione: (2026)
• Beyond Monotherapy: The Superior Efficacy of Combined GLP ‐1 Receptor Agonist and SGLT2 Inhibitors on Renal Biomarkers: A Systematic Review and Meta‐Analysis
  di: Aya M. AbdelMagid, et al.
  Pubblicazione: (2026)
• Insulin requirements after switching from GLP ‐1 receptor agonist to dual GIP / GLP ‐1 receptor agonist in patients with type 2 diabetes mellitus
  di: Alexa M. Lahey, et al.
  Pubblicazione: (2025)